WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR April 2024 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • WJAHR: APRIL ISSUE PUBLISHED

    APRIL 2024 Issue has been successfully launched on APRIL 2024.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

A COMPARATIVE STUDY ON TOLERABILITY AND QUALITY OF LIFE OF COLORECTAL CANCER PATIENTS ON FOLFOX AND CAPOX REGIMEN

*Fouziya Begum, Ayesha Saffura, Vunnamatla Manish and K. Jigeesha Reddy

ABSTRACT

Objective: The study aimed to compare the Tolerability and Quality of life of Colorectal Cancer patients on FOLFOX (leucovorin, 5fluorouracil and oxaliplatin) and CAPOX (capecitabine and oxaliplatin) regimens. Methodology: A total of 102 colorectal cancer patients On FOLFOX and CAPOX regimens were prospectively analysed for 6months. The data was gathered from patients’ Case sheets and by interviewing the patients. The tolerability and Quality of life of these two regimens were compared by using the CTCAE grading system and two functional questionnaires Viz., EORTC QLQ C-30, and FACT-C version 4 respectively. Statistical tools like the independent sample t-test and Chi-square test were applied to the data using SPSS Software. Results: Among 102 patients, 52(50.9%) were on FOLFOX and 50(49.01%) were on the CAPOX regimen. male (64.7%) patients were predominant compared to female (35.3%) patients. CTCAE Grade3 peripheral sensory neuropathy, Diarrhoea, Vomiting and treatment discontinuation were significantly higher in CAPOX compared to FOLFOX. A Significantly High EORTC QLQ C-30 Global health quality of life and a higher level of functioning were observed in FOLFOX compared to the CAPOX group. However, higher levels of problems or symptomatology were observed in CAPOX. There is a significantly higher FACT-C total score was observed in the FOLFOX group, indicating higher quality of life in FOLFOX. Conclusion: The Tolerability of FOLFOX was higher compared to CAPOX. Both EORTC QLQ-C30 and FACT C scores concluded better quality of life in FOLFOX compared to CAPOX. Moreover, Treatment discontinuation was higher in the CAPOX group.

[Full Text Article] [Download Certificate]